There is no single best growth hormone peptide. Sermorelin, CJC-1295, and tesamorelin all act on the GH axis as GHRH analogs, while ipamorelin works through a separate ghrelin receptor. The right one depends on your baseline IGF-1 and your goal.
The best growth hormone peptide is the one matched to your baseline IGF-1 and your clinical goal, not a universal winner. Four peptides dominate legitimate telehealth: sermorelin, CJC-1295, ipamorelin, and tesamorelin. Three are GHRH analogs that stimulate the pituitary to release its own growth hormone [1]. One, ipamorelin, is a selective GH secretagogue that acts on the ghrelin receptor instead [2]. That mechanistic split is what decides which peptide, or which pair, fits a given patient.
- There is no universal best GH peptide; the right one depends on baseline IGF-1 and goal.
- Sermorelin, CJC-1295, and tesamorelin are GHRH analogs; ipamorelin is a GHRP on a separate receptor.
- CJC-1295 with DAC has a 6 to 8 day half-life for weekly dosing; sermorelin is dosed nightly.
- Tesamorelin is FDA-approved for HIV lipodystrophy only; other GH-axis peptide use is compounded.
- For most patients a GHRH analog paired with ipamorelin outperforms either peptide alone.
The Two Mechanisms Behind Every GH Peptide
Every GH-axis peptide belongs to one of two classes. GHRH analogs (sermorelin, CJC-1295, tesamorelin) copy growth hormone-releasing hormone and bind GHRH receptors on the anterior pituitary, prompting it to release its own GH. GHRPs (ipamorelin) copy ghrelin, act on a separate receptor, and blunt somatostatin. Because the two classes hit different receptors, giving one of each produces a larger GH release than either alone [3].
- GHRH analogs: sermorelin, CJC-1295, tesamorelin. They stimulate pituitary GH release.
- GHRP: ipamorelin. It triggers a GH pulse through the ghrelin receptor and suppresses somatostatin.
- Both classes keep the somatostatin feedback loop intact, so GH output stays self-limited.
- A GHRH analog paired with ipamorelin is the standard stack because the two mechanisms add together.
Sermorelin: The Baseline GHRH Analog
Sermorelin is the shortest-acting and most-studied GHRH analog in adult practice. It is a 29-amino acid peptide dosed at 100 to 300 mcg subcutaneously at bedtime, timed to the natural overnight GH pulse. IGF-1 rises within about 2 weeks, and the response peaks near 90 days, which is why the standard checkpoint is a 90-day IGF-1 retest [4]. Its short half-life means a nightly injection, which is the main trade-off.
CJC-1295: The Long-Acting GHRH Analog
CJC-1295 solves the frequent-dosing problem of sermorelin. The DAC (drug affinity complex) version binds albumin and extends the half-life to 6 to 8 days, so IGF-1 stays raised for over a week from a single injection [5]. The no-DAC version, often labeled modified GRF 1-29, is short-acting and dosed like sermorelin. Prolonged CJC-1295 dosing sustains IGF-1 [6], and pulsatile GH release persists even under the steady stimulation, which is why it does not flatten secretion the way a continuous infusion would [7].
Ipamorelin: The Selective GHRP
Ipamorelin is the GHRP of choice because it is selective. It triggers a clean GH pulse without the cortisol or prolactin rise seen with older secretagogues [2], and it has been tested in controlled human trials [8]. On its own it is a modest GH stimulus. Its real role is as the second half of a stack, paired with a GHRH analog so the two mechanisms combine.
Tesamorelin: The FDA-Approved GHRH Analog
Tesamorelin is the only GH-axis peptide with an active FDA approval, and that approval covers HIV-associated visceral fat, not anti-aging. It is a stabilized GHRH analog with the strongest trial evidence for reducing visceral and abdominal fat at 2 mg daily [9]. Its FDA-approved labeling applies only to the HIV lipodystrophy indication [10]. Any use for general body composition is off-label and, in practice, compounded.
Which Peptide for Whom
The choice follows the goal, not the marketing. Match the peptide to what your labs and objective actually call for.
| Peptide | Class | Dosing | Best fit | Trade-off |
|---|---|---|---|---|
| Sermorelin | GHRH analog | 100 to 300 mcg nightly | A first GH-axis trial with age-related low IGF-1 | Nightly injection, shortest action |
| CJC-1295 (DAC) | GHRH analog | About weekly (6 to 8 day half-life) | Patients who want infrequent dosing | Sustained elevation, less physiologic rhythm |
| Ipamorelin | GHRP | Nightly, stacked | Second peptide to amplify a GHRH analog | Weak as a monotherapy |
| Tesamorelin | GHRH analog | 2 mg daily | Documented visceral fat reduction | Highest cost; FDA label is HIV-only |
Why the Stack Usually Wins
For most patients the practical answer is not a single peptide but a GHRH analog paired with ipamorelin. CJC-1295 with ipamorelin is the common version: one drives steady GHRH signaling, the other adds a ghrelin-receptor pulse and blunts somatostatin. The combined GH release is larger than either peptide alone, the same additive effect shown when a GHRH and a GHRP are given together [3].
Start From Labs, Not From a Peptide Name
The mistake is picking a peptide before knowing your numbers. A baseline IGF-1 is the reference point any of these should be prescribed against, because it establishes whether the GH axis is actually low and gives you a value to measure the 90-day response against [4]. A program that names a peptide before it draws your labs has the order backwards. Skipping the baseline is a consistent red flag.
The right GH-axis peptide depends on a baseline IGF-1, and most programs skip it. SystemLabs tests IGF-1 before prescribing and formulates sermorelin, CJC-1295, and ipamorelin protocols on clinical indication, so the peptide is chosen from your numbers and a 90-day retest measures the response.
Bottom Line
Frequently Asked Questions
What is the best growth hormone peptide?
There is no single best growth hormone peptide. The right choice depends on your baseline IGF-1 and your goal. Sermorelin suits a first GH-axis trial, CJC-1295 with DAC suits patients who want weekly rather than nightly dosing, ipamorelin works as the second peptide in a stack, and tesamorelin has the strongest evidence for visceral fat but is FDA-approved only for HIV lipodystrophy. Most patients do best on a GHRH analog paired with ipamorelin.
Is CJC-1295 better than sermorelin?
CJC-1295 and sermorelin are both GHRH analogs with the same mechanism. The difference is duration. Sermorelin is short-acting and dosed nightly. CJC-1295 with DAC has a 6 to 8 day half-life and is dosed about weekly. Neither is stronger at the receptor; CJC-1295 mainly reduces how often you inject.
Should I stack ipamorelin with a GHRH peptide?
Ipamorelin is usually stacked rather than used alone. It is a GHRP that acts on the ghrelin receptor, a different target from GHRH analogs like sermorelin and CJC-1295. Combining the two classes produces a larger GH pulse than either alone, which is why CJC-1295 with ipamorelin is the standard pairing.
Is tesamorelin the strongest GH peptide?
Tesamorelin has the strongest trial evidence for reducing visceral fat and is the only GH-axis peptide with an active FDA approval, but that approval covers HIV-associated lipodystrophy, not anti-aging or general body composition. Used outside that indication it is off-label and compounded. Strongest evidence for one indication does not make it the right choice for every goal.
Do I need labs before starting a GH peptide?
Yes. A baseline IGF-1 test is required before any GH-axis peptide is prescribed. It confirms whether your GH axis is actually low and gives a starting value to measure the 90-day response against. A provider that prescribes a peptide before drawing baseline labs is a red flag.
References
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMID: 18046908. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- EGRIFTA SV (tesamorelin) for injection: full prescribing information DailyMed, U.S. National Library of Medicine, 2025. FDA-approved labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
